In Brief: Merck Aggrastat
Executive Summary
Merck Aggrastat: Ongoing trials are called Platelet Receptor Inhibition for Ischemic Syndrome Management (PRISM) and Platelet Receptor Inhibition for Ischemic Syndrome Management in Patients Limited to Unstable Signs and Symptoms (PRISM PLUS). "The Pink Sheet" (April 1, T&G-8) reported the incorrect acronym...